Steven Quay, a physician and pharmaceutical executive who has written extensively on the theory that COVID-19 originated in a laboratory, is undergoing final vetting to lead the National Institute of Allergy and Infectious Diseases (NIAID). Two sources, including a senior Department of Health and Human Services (HHS) official and an individual outside of government, confirmed the selection process to POLITICO. The role, which does not require Senate confirmation, would place Quay at the head of the agency formerly led by Anthony Fauci.
The NIAID has been without a permanent director since Health Secretary Robert F. Kennedy Jr. dismissed Jeanne Marrazzo last year. Marrazzo, who was appointed following Fauci's retirement in 2022, is currently suing Kennedy and other officials, alleging her termination was retaliation for her stance on vaccines and research collaborations. While Quay applied for the role through a general call for applicants last year, he was initially not advanced by National Institutes of Health (NIH) staff. However, Secretary Kennedy chose Quay over other finalists, and the NIH reportedly approved the hire last week.
Quay is the founder of several pharmaceutical companies, including Atossa Therapeutics, and would be the first NIAID director to come directly from the private drug industry rather than academia or the NIH. He has authored two books arguing that the COVID-19 genome indicates a laboratory origin and testified before a 2024 Senate panel that certain virologists engaged in "academic fraud" regarding the pandemic's beginnings. While some U.S. agencies like the FBI and Energy Department lean toward the lab-leak theory, many scientists and a World Health Organization report maintain that a natural spillover from animals remains the more likely cause.
A person would notice these changes primarily through the types of medical treatments and public health guidance that receive federal backing. Quay has publicly advocated for NIAID to shift its focus toward "faster therapeutics" and increased research into antibiotic-resistant bacteria. He has also proposed new mandates for high-risk research, such as "watermarking" engineered pathogens to track their origin labs and establishing third-party review panels. These changes would likely begin to manifest in agency grant requirements and federal research protocols shortly after he takes office, potentially slowing some types of virology research while accelerating others.
The appointment also signals a departure from the 40-year precedent of the NIAID director acting as a non-political career scientist. This could lead to further shifts in how federal agencies manage "gain-of-function" research—studies that make viruses more transmissible to better understand them—which HHS recently moved to halt. While the vetting is in its final stages, the exact date for a formal announcement has not been reported. The hire follows a period of significant turnover at the agency, which is currently overseen by acting director John Powers III.